Poseida Therapeutics (NASDAQ:PSTX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.

Poseida Therapeutics Price Performance

PSTX opened at $2.67 on Friday. The firm has a market capitalization of $260.23 million, a PE ratio of -4.24 and a beta of 0.54. Poseida Therapeutics has a 1 year low of $1.87 and a 1 year high of $4.27. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 3.20. The business’s 50-day moving average is $2.81 and its two-hundred day moving average is $2.92.

Hedge Funds Weigh In On Poseida Therapeutics

Hedge funds have recently modified their holdings of the stock. Marshall Wace LLP purchased a new stake in Poseida Therapeutics during the 2nd quarter worth approximately $31,000. Bayesian Capital Management LP purchased a new stake in Poseida Therapeutics during the 1st quarter valued at about $33,000. Rothschild Investment LLC acquired a new position in shares of Poseida Therapeutics in the second quarter valued at about $35,000. Principal Financial Group Inc. purchased a new position in shares of Poseida Therapeutics in the second quarter worth about $35,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Poseida Therapeutics during the third quarter worth about $46,000. Institutional investors and hedge funds own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.